Drugs / LT-010391
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07624214 | Jul 2026 → Apr 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LT-010391 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07624214 ↗ |
| Route | Oral | “LT-010391 tablets, oral, once daily” NCT07624214 ↗ |
| Target | KRAS | “KRAS G12D degrader” NCT07624214 ↗ |